Brief: Meiragtx Announces Positive Clinical Data From Early-Stage Study Of Radiation-Induced Dry Mouth Treatment

MeiraGTx Holdings

27/06/2023 13:20

June 27 (Reuters) - MeiraGTx Holdings PLC  MGTX.O :
    * MEIRAGTX ANNOUNCES POSITIVE CLINICAL DATA FROM THE AQUAX
PHASE 1
CLINICAL STUDY OF AAV2-HAQP1 FOR THE TREATMENT OF GRADE 2/3
RADIATION-INDUCED XEROSTOMIA
    * MEIRAGTX HOLDINGS PLC - ACROSS ASSESSMENTS, GREATER
IMPROVEMENTS
OBSERVED IN BILATERALLY TREATED PARTICIPANTS COMPARED TO THOSE
TREATED UNILATERALLY
    * MEIRAGTX HOLDINGS PLC - EARLY LONG-TERM FOLLOW-UP DATA
SUGGEST
DURABILITY OF IMPROVEMENT TO AT LEAST 3 YEARS POST-TREATMENT
    * MEIRAGTX HOLDINGS PLC - AAV2-HAQP1 APPEARS SAFE AND WELL
TOLERATED AT EACH DOSE TESTED
    * MEIRAGTX HOLDINGS PLC - STRONG SAFETY AND ENCOURAGING,
CLINICALLY MEANINGFUL ACTIVITY DATA SUPPORT FURTHER CLINICAL
DEVELOPMENT OF AAV2-HAQP1
    * MEIRAGTX HOLDINGS PLC - PHASE 2 RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED STUDY INITIATED WITH PARTICIPANTS CURRENTLY
BEING DOSED
    * MEIRAGTX HOLDINGS PLC - FULL DATA FROM AQUAX PHASE 1 STUDY
IS
EXPECTED TO BE REPORTED AT A SCIENTIFIC MEETING IN SECOND HALF
OF 2023
    * MEIRAGTX HOLDINGS PLC - NO DOSE-LIMITING TOXICITY OR
TREATMENT-RELATED SERIOUS ADVERSE EVENTS

Source text for Eikon:  ID:nGNX796W1h 
Further company coverage:  MGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))